Administer VYXEOS by the intravenous route only. Confirm patency of intravenous access before administration. Do not administer by intramuscular or subcutaneous route.

For the first cycle of induction, the recommended dose of VYXEOS is (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) liposome administered via intravenous infusion over 90 minutes on days 1, 3,...

Jul 1, 2025 · Administer VYXEOS by constant intravenous infusion over 90 minutes via an infusion pump through a central venous catheter or a peripherally inserted central catheter.

EW DATE: 12/18/2024 OVERVIEW Vyxeos is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, nucleoside metabolic inhibitor. It is indicated …

VYXEOS (daunorubicin and cytarabine) liposome for injection is a combination of daunorubicin and cytarabine in a 1:5 molar ratio encapsulated in liposomes for intravenous administration.

INDICATIONS AND USAGE VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults …

Administration Vyxeos should be administered in 500mL sodium chloride 0.9% over 90 minutes. It should be administered via an infusion pump through a central venous catheter or a peripherally …

VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 …

DAUNOrubicin-cytarabine liposome (VYXEOS) 44 mg/m2 in sodium chloride 0.9% 500 mL chemo IVPB Dose: 44 mg/m2 Route: intravenous once over 120 Minutes for 1 dose Offset: 30 Minutes …

Jul 7, 2025 · Vyxeos package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.